Search
Changchun High-tech Industries: Subsidiary's Clinical Trial Registration Application for GenSci143 Injection Approved
2025-08-21 /
Read about 0 minute
Author：小编
Changchun High-tech Industries has announced that its subsidiary, Jinsai Pharmaceutical, has secured approval from the National Medical Products Administration for the registration of clinical trials for GenSci143 Injection, an independently developed drug by Jinsai Pharmaceutical. GenSci143 is a bispecific antibody-drug conjugate specifically targeting B7-H3 and PSMA, offering dual therapeutic potential through targeted chemotherapy and tumor immunity. This innovative drug is poised to offer a novel treatment option for a broad range of solid tumors expressing B7-H3 and/or PSMA.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
